The expression of ABO(H) blood group antigens causes deletion of cells that generate self-specific antibodies to these antigens but this deletion limits adaptive immunity toward pathogens bearing cognate blood group antigens. To explore potential defense mechanisms against such pathogens, given these limitations in adaptive immunity, we screened for innate proteins that could recognize human blood group antigens. Here we report that two innate immune lectins, galectin-4 (Gal-4) and Gal-8, which are expressed in the intestinal tract, recognize and kill human blood group antigen-expressing Escherichia coli while failing to alter the viability of other E. coli strains or other Gram-negative or Gram-positive organisms both in vitro and in vivo. The killing activity of both Gal-4 and Gal-8 is mediated by their C-terminal domains, occurs rapidly and independently of complement and is accompanied by disruption of membrane integrity. These results demonstrate that innate defense lectins can provide immunity against pathogens that express blood group-like antigens on their surface.
Recent studies suggest that blood group antigen diversity may provide a mechanism of pathogen evasion whereby distinct ABO(H) antigen structures may reduce pathogen attachment and therefore infectivity 1 . However, expression of ABO(H) blood group antigens causes deletion of cells that would produce antibodies to these antigens, which limits adaptive immunity toward pathogens bearing blood group-like structures. Because ABO(H) antigens are composed of carbohydrate structures that only differ by distinct monosaccharides on the terminal structures of glycans 2 , factors that might be responsible for providing innate immunity toward pathogens expressing blood group antigens must recognize carbohydrates. A growing list of glycanbinding proteins, including galectins and C-type lectins, recognize carbohydrate determinants on pathogens and participate in innate immune responses [3] [4] [5] . Notably, previous studies suggest that several galectins may recognize blood group antigens 6 along with various other carbohydrate ligands. Given the ability of innate immune lectins to recognize cell surface carbohydrates, we explored the carbohydrate binding of several innate immune lectins for potential blood group binding specificity and subsequent activity.
RESULTS

Galectins recognize blood group-positive bacteria
We analyzed publicly available data from the screening of nearly 100 different lectins from the Consortium for Functional Glycomics, many of which are mammalian lectins with documented immunological activity, including members of the galectin family. Members of the galectin family had some of the most specific interactions observed among the lectins tested after screening of over 300 structurally diverse glycans. Human Gal-3, Gal-4 and Gal-8, which recognize multiple glycan structures at relatively high concentrations 6, 7 , showed specificity for human blood group A and B antigens at submicromolar concentrations and did not bind blood group O(H) at these concentrations, whereas human Gal-1, a related galectin family member, did not recognize blood group antigens ( Fig. 1a-d) . This specificity was not as striking in our previous studies concerning members of this protein family, where we tested binding at high protein concentrations and found that the lectins recognized multiple carbohydrate ligands along with blood group antigens 6, 7 .
Bacteria generate a wide variety of glycan-based antigenic structures, many of which can possess blood group antigen activity 8, 9 . The best characterized of these, E. coli O86, cross-reacts with antibodies specific for human blood group B and induces high titers of blood group B-specific antibodies in previously unexposed individuals 10 . Notably, whereas individuals of blood group A or O produce antibodies that kill E. coli O86, individuals with blood group B do not generate antibodies capable of altering E. coli O86 viability 10, 11 , providing a specific example of the immunological limitation in adaptive immunity toward a blood group antigen-bearing pathogen. The ability of human Gal-3, Gal-4 and Gal-8 to specifically recognize blood group A and B antigens suggests that they may be uniquely poised to provide innate immunity toward blood group-bearing pathogens regardless of the blood group antigen status of an individual. However, although E. coli O86 generates an identical blood group B epitope (Fig. 1e) to that of humans 12 , the context of this epitope may differ from the common Innate immune lectins kill bacteria expressing blood group antigen human presentations found on the glycan microarray. Therefore, we examined whether Gal-3, Gal-4 and Gal-8 recognize E. coli O86. Consistent with their ability to specifically recognize blood group A and B antigens on the glycan microarray, human Gal-3, Gal-4 and Gal-8, but not Gal-1, bound E. coli O86, hereafter referred to as blood group B-positive E. coli (BGB + E. coli) (Fig. 1f-i) . Binding of all galectins to bacteria was inhibited by lactose, an inhibitor of galectincarbohydrate interactions (Fig. 1f-i) , indicating that galectin bound glycan determinants on the surface of BGB + E. coli.
Gal-4 and Gal-8 kill blood group-positive bacteria
Previous studies showed high galectin expression in the intestinal mucosa, where the galectins may serve as pathogen recognition proteins 13, 14 , suggesting that Gal-3, Gal-4 and Gal-8 may facilitate innate immunity toward BGB + pathogens. Although previous studies have shown that several innate immune lectins can directly affect pathogen viability 3, 15, 16 , indicating potential roles for galectins in pathogen adhesion, recognition and killing 14 , there is no direct evidence as to whether galectins can alter prokaryote viability. Thus, we asked whether Gal-3, Gal-4 and Gal-8 might confer intrinsic immunity by directly killing BGB + E. coli. Incubation with both Gal-4 and Gal-8 caused direct killing of BGB + E. coli, whereas Gal-3, which also binds BGB + E. coli, did not affect viability, and Gal-1, which does not bind BGB + E. coli, had no effect (Fig. 2a) . As expected, lactose completely inhibited both Gal-4-and Gal-8-induced death, whereas sucrose, a disaccharide unable to inhibit galectin-carbohydrate interactions, failed to alter killing of BGB + E. coli (Fig. 2b,c) . Gal-4 and Gal-8 showed similarly potent concentration-dependent killing of BGB + E. coli, with a half-maximal lethal dose of ~0.1 µM (Fig. 2d) , a concentration similar to that observed in vivo 17 and used to evaluate glycan binding specificity on the glycan microarray. In addition, the effects of Gal-8 treatment seemed to be rapid, as treated BGB + E. coli lost all motility compared to untreated BGB + E. coli shortly after the addition of Gal-8 ( Fig. 2e and Supplementary Video 1) . BGB + E. coli positively stained for propidium iodide after a 30 min incubation with Gal-8 ( Fig. 2f) and showed considerable disruption of membrane morphology (Fig. 2g,h) . These results show that Gal-8 kills BGB + E. coli by directly altering membrane integrity. We observed comparable alterations after incubation with Gal-4 (data not shown). Taken together, these results show that both human Gal-4 and Gal-8 directly kill BGB + E. coli through recognition of bacterial surface carbohydrates via a mechanism that drastically alters membrane integrity and bacterial motility. Killing of BGB + E. coli by human Gal-4 and Gal-8 did not require complement (Fig. 2) , demonstrating that these lectins fundamentally differ from other innate immune lectins, such as mannan-binding proteins, which do not directly alter viability but activate complement after pathogen recognition 16 .
Unlike Gal-1 and Gal-3, which contain a single carbohydrate recognition domain (CRD), Gal-4 and Gal-8 have two distinct CRDs 18 , suggesting that these galectins may use one domain for target recognition and the other domain for killing the target once bound, similarly to many prokaryotic AB toxins 19 . To distinguish these possibilities, we mutated each CRD of Gal-8, as done previously 6, 7 in the context of the whole protein, to determine which domain recognizes BGB + E. coli. Inactivation of the C-terminal CRD (R233H) (Gal-8R233H) eliminated recognition of blood group antigens on both the glycan microarray and BGB + E. coli, whereas the analogous mutation in the N-terminal CRD (R69H) (Gal-8R69H) did not alter blood group antigen recognition in either context (data not shown). Of note, Gal-8R69H, but not Gal-8R233H, killed BGB + E. coli (Fig. 3a) , which indicates that Gal-8-mediated killing requires carbohydrate recognition only by the blood group-binding C-terminal domain of Gal-8. To determine whether the N-terminal domain is required for Gal-8 killing independently of glycan recognition, we expressed the individual domains of Gal-8. Whereas the N-terminal domain (Gal-8N) failed to bind blood group antigens on either the glycan microarray or BGB + E. coli ( Fig. 3b and data not shown), the C-terminal domain of Gal-8 (Gal-8C) independently recognized blood group antigens and killed BGB + E. coli (Fig. 3b,c) . These results show that recognition and killing of BGB + E. coli by Gal-8 resides entirely within its blood group-binding domain. By contrast, both domains of Gal-4 showed specific recognition of BGB + E. coli (Fig. 3d) . Thus, we asked whether Gal-4N and Gal-4C might independently kill BGB + E. coli. However, similar to Gal-3, Gal-4N showed substantial recognition of BGB + E. coli yet failed to alter BGB + E. coli viability (Figs. 2a and 3e). By contrast, Gal-4C had substantial killing activity toward BGB + E. coli (Fig. 3e) . Notably, the Gal-4C and Gal-8C domains show phylogenetic similarities not shared by Gal-3 and the Gal-4N domain 20 , which suggests a conserved mechanism shared between these two protein domains.
Galectin killing requires blood group antigen recognition
The ability of the blood group-binding domain of Gal-4 and Gal-8 to independently kill BGB + E. coli (Fig. 3a,c,e) suggested that Gal-4 and Gal-8 might specifically kill BGB + E. coli. To test this, we examined whether Gal-4 and Gal-8 recognize strains of E. coli that fail to express the blood group B-related antigen. Although both Gal-4 and Gal-8 recognize BGB + E. coli, they did not substantially bind or affect the viability of BGB -E. coli (Fig. 4a-c and data not shown). In addition, Gal-4 and Gal-8 did not recognize or kill the Gram-negative, BGB -species Klebsiella pneumoniae and Pseudomonas aeruginosa, and they neither bound nor altered the viability of Gram-positive Staphylococcus aureus (Fig. 4d-g and data not shown). We next asked whether Gal-8 specifically kills BGB + E. coli in a mixed population of BGB + and BGB − bacteria. We incubated GFP + BGB − P. aeruginosa with Gal-8 to determine whether Gal-8 altered GFP expression or viability. Gal-8 failed to alter GFP expression (Fig. 4h) (Fig. 4i,j) . Furthermore, defined mutations that prevent synthesis of the blood group antigen formation on BGB + E. coli (∆waaL) prevented recognition and killing by Gal-4 and Gal-8, whereas bacteria carrying mutations that allow formation of at least one repeat of the blood group antigen (∆wzy) remained sensitive to Gal-4 and Gal-8 ( Fig. 5a-d) , further illustrating the specificity of Gal-4 and Gal-8 for the blood group B antigen 21 . Of note, lactose, but not sucrose, prevented Gal-4 and Gal-8 killing (data not shown). Notably, although both Gal-4 and Gal-8 recognized BGB + human erythrocytes, neither affected the membrane integrity of these cells (data not shown), which indicates that the killing activity of Gal-4 and Gal-8 not only shows antigen specificity but also uniquely targets prokaryotes. Furthermore, Gal-4-and Gal-8-induced killing of BGB + E. coli did not represent a simple agglutination-associated reduction in colony-forming unit (CFU) counts, as Gal-4 and Gal-8 bound BGB + E. coli at 4 °C but did not alter viability (data not shown). In addition, both Gal-1 and human BGB-specific antibodies recognized and agglutinated BGB + E. coli at high concentrations, yet failed to affect CFU counts of BGB + E. coli after incubation with the bacteria (data not shown).
Whereas these results show that Gal-4 and Gal-8 kill BGB + E. coli in vitro, we used mice to test whether similar activities occur in vivo. We first examined whether the mouse galectin-4 (Gal-4) possesses a similar ability to bind and kill BGB + E. coli to human Gal-4. Recombinant mouse Gal-4 recognized BGB + E. coli, and the recognition was inhibited by both lactose (Fig. 6a) and thiodigalactoside, a nonmetabolizable inhibitor of galectins (data not shown). Furthermore, mouse Gal-4 recognition of BGB + E. coli seemed to be specific to the BGB antigen, as mouse Gal-4 failed to recognize the ∆waaL mutant (Fig. 6b) , similar to human Gal-4 (data not shown). Mouse Gal-4 also showed high binding of blood group antigens on the glycan microarray (Fig. 6c) .
Of note, mouse Gal-4 recognition of BGB + E. coli resulted in a substantial reduction in viability, which seemed to be specific to BGB antigen binding, as mouse Gal-4 failed to alter the viability of the ∆waaL mutant (Fig. 6d) , and Gal-4-mediated killing was inhibited by thiodigalactoside (data not shown). However, mouse Gal-4-mediated killing was less potent when compared to human Gal-4, possibly owing to the reduced affinity of mouse Gal-4 for BGB when compared to BGA (Fig. 6c,d ).
Galectins specifically kill BGB + bacteria in vivo
The selective killing of BGB + E. coli by mouse Gal-4 suggests that the ∆waaL mutant should show better growth in vivo as a result of the inability of endogenous galectins to bind and kill these bacteria, whereas BGB + E. coli should be limited in their growth owing to killing by endogenous Gal-4 and Gal-8. It has been shown previously that Gal-4 and Gal-8 are the only intestinal proteins that detectably bind β-galactosides 22 , but Gal-4 and Gal-8 double-knockout mice are not available, and such mice may not be viable. Thus, to specifically test the physiological functions of these intestinal galectins, we fed wild-type (WT) mice with BGB + E. coli or ∆waaL mutant E. coli. In this in vivo model, we first treated mice with streptomycin to deplete endogenous bacteria followed by feeding the mice with the WT and ∆waaL mutant strains of bacteria. The number of WT bacteria detected was significantly lower in vivo compared to the ∆waaL mutant (Fig. 6e) , although both types of bacteria showed equal growth kinetics in vitro (data not shown), which implicated a possible galectin-mediated process in vivo.
The few bacteria isolated from mice inoculated with WT bacteria were positive for BGB antigen. Similarly, bacteria isolated after introduction of the ∆waaL mutant were negative for the BGB antigen, indicating that the bacteria examined reflected those used during the inoculation (data not shown).
To test the potential role of galectins in the observed difference in growth of the two types of bacteria, we incubated BGB + E. coli or ∆waaL E. coli with or without the inclusion of thiodigalactoside in vivo. Although thiodigalactoside failed to alter the growth of BGB + E. coli or ∆waaL E. coli in the absence of mGal-4 (data not shown), thiodigalactoside significantly increased BGB + E. coli viability in vivo while failing to alter ∆waaL E. coli viability (Fig. 6f) . These results strongly suggest that endogenous galectins specifically alter the viability of BGB + E. coli in vivo. Although blood group antigens are expressed to some extent in glycosphingolipids and mucins of the gastrointestinal tract 23 , it has been found that they are susceptible to degradation by bacterial-derived glycosidases 24, 25 , and in infants this bacterial-induced degradation of blood group antigens is observed soon after weaning 26 . Thus, it is not likely that host blood group antigens, which are expressed in low amounts, can bind all of the galectins present, as Gal-4 and Gal-8 are highly expressed in the intestinal tract 27, 28 .
Although Gal-4 and Gal-8 seem to kill specifically BGB + E. coli, whether Gal-4 or Gal-8 possess the ability to recognize and kill bacteria expressing other types of blood group antigens remained unknown. To test this, we examined whether Gal-4 and Gal-8 could recognize and kill bacteria expressing the α1-3Gal epitope (α-Gal E. coli), a common glycan moiety found in many mammalian species (Fig. 6g) . Similar to BGB + E. coli, α-Gal E. coli were recognized by Gal-4 and Gal-8 (Fig. 6h) , and recognition was inhibited by thiodigalactoside (data not shown). Furthermore, Gal-4 and Gal-8 recognition of α-Gal E. coli resulted in a considerable decrease in viability (Fig. 6i) , although killing of α-Gal E. coli by Gal-4 and Gal-8 was reduced when compared to Gal-4-and Gal-8-mediated killing of BGB + E. coli, suggesting a possible reduced binding affinity toward this glycan epitope. Consistent with this, Gal-4 and Gal-8 only recognized α-Gal epitopes on the glycan array when incubated at higher concentrations 7 (data not shown). Taken together, these results demonstrate that Gal-4 and Gal-8 possess the ability to specifically kill bacteria expressing common blood group-associated mammalian-like antigens.
DISCUSSION
Many human pathogens decorate their surfaces with diverse carbohydrate structures, and many of these structures have similarities to human antigens, a common mechanism used by both commensal and pathogenic organisms to render themselves immunologically inert. However, mechanisms must also be in place to prevent the overgrowth of any potential pathogens that are shielded from normal adaptive immune responses. Thus, the ability of Gal-4 and Gal-8 to specifically kill BGB + E. coli extends previous observations suggesting crucial roles for galectins in innate immunity 14 and may reflect a common but unrealized feature of other innate immune lectins to provide direct protection against pathogens expressing particular self-like antigens, where adaptive immunity cannot.
Similar to many innate immune factors, the galectins represent an ancient family of proteins present in a wide variety of species 20 . As galectins evolved long before the selection of adaptive immunity, it is intriguing to speculate that the types of carbohydrate modifications on some self-antigens, such as blood group antigens, may reflect the binding specificity of preexisting innate immune factors such as the galectins. The generation of ABO(H) antigen diversity in the human population has been proposed to facilitate pathogen evasion during human evolution 1 . For example, differential expression of blood group ABO(H) antigens in host tissues can differentially affect pathogen adhesion and infection, as recently shown for Helicobacter pylori 29 . However, this diversity might have arisen with a considerable fitness cost, as development of these antigens precludes adaptive immune responses against blood group antigen-bearing pathogens. The ability of galectins to recognize blood group antigen-bearing pathogens may have facilitated the selection of ABO(H) expression on human erythrocytes rather than alternative antigens that did not have the same preexisting innate immune protection. In contrast, the ability of Gal-4 and Gal-8 to also kill α-Gal-expressing bacteria shows that galectin-mediated killing is not limited to human blood group antigenexpressing bacteria and suggests that galectins may affect the composition of multiple populations of intestinal bacteria, thereby modulating the intestinal microbiome. Future studies will examine these possibilities.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
